Fennec Pharmaceuticals (TSE:FRX) Hits New 52-Week Low at $8.16

Fennec Pharmaceuticals Inc. (TSE:FRX)’s share price reached a new 52-week low on Wednesday . The stock traded as low as C$8.16 and last traded at C$8.16, with a volume of 4000 shares changing hands. The stock had previously closed at C$8.26.

Fennec Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of C$10.20 and a two-hundred day simple moving average of C$12.50. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 6.93. The firm has a market capitalization of C$222.93 million, a P/E ratio of 163.20 and a beta of 0.46.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share for the quarter, missing the consensus estimate of C$0.67 by C($0.11). The firm had revenue of C$34.21 million for the quarter, compared to the consensus estimate of C$14.19 million. Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. As a group, equities analysts forecast that Fennec Pharmaceuticals Inc. will post 1.1958225 EPS for the current year.

Insider Transactions at Fennec Pharmaceuticals

In other news, Senior Officer Adrian J. Haigh sold 22,223 shares of the business’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of C$9.32, for a total value of C$207,029.47. Insiders have sold a total of 25,454 shares of company stock valued at $230,291 in the last ninety days. 17.27% of the stock is currently owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.